Business Standard

Saturday, December 21, 2024 | 12:01 AM ISTEN Hindi

Notification Icon
userprofile IconSearch

First copies of Gilead coronavirus drug to start selling in Bangladesh

The Dhaka-based Beximco, which counts Norges Bank as one of its investors, will sell remdesivir for about 6,000 taka ($71) a vial to private clinics but will give it free to state-run hospitals

pharma
Premium

Beximco Pharmaceuticals will sell the generic version Gilead Sciences' antiviral drug.

Bloomberg
Bangladesh’s Beximco Pharmaceuticals has become the world’s first company to start selling the generic version of Gilead Sciences’ antiviral drug on mounting urgency to treat the infection caused by the coronavirus.
 
The Dhaka-based Beximco, which counts Norges Bank as one of its investors, will sell remdesivir for about 6,000 taka ($71) a vial to private clinics but will give it free to state-run hospitals treating Covid-19 patients, Rabbur Reza, chief operating officer at the company, said in an interview.

AstraZeneca gets order of $1 bn from US 

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in